# First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

> **NCT06402201** · PHASE1 · RECRUITING · sponsor: **CDR-Life AG** · enrollment: 42 (estimated)

## Conditions studied

- Select Advanced Solid Tumors

## Interventions

- **BIOLOGICAL:** CDR404

## Key facts

- **NCT ID:** NCT06402201
- **Lead sponsor:** CDR-Life AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06402201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06402201, "First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06402201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*